Increlex(mecasermin)
Increlex (mecasermin) is a protein pharmaceutical. Mecasermin was first approved as Increlex on 2005-08-30. It has been approved in Europe to treat laron syndrome. The pharmaceutical is active against insulin-like growth factor I. In addition, it is known to target insulin-like growth factor 1 receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Increlex
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| aqua de folli hair booster | unapproved drug other | 2020-10-05 |
| aqua de folli hair booster mini | unapproved drug other | 2020-10-05 |
| aqua de folli hair booster pro | unapproved drug other | 2020-10-05 |
| hucord hscm-100 ampoule | unapproved drug other | 2019-12-23 |
| increlex | Biologic Licensing Application | 2024-03-20 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
mecasermin, Increlex, Ipsen Biopharmaceuticals, Inc. | |||
| 2112-08-30 | Orphan excl. | ||
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J2170 | Injection, mecasermin, 1 mg |
Clinical
Clinical Trials
316 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acromegaly | D000172 | — | — | — | 4 | 9 | 6 | 13 | 32 |
| Laron syndrome | D046150 | Orphanet_633 | E34.321 | 2 | 6 | 3 | 4 | 5 | 18 |
| Dwarfism | D004392 | HP_0003510 | E34.31 | 1 | 4 | 2 | 2 | 6 | 13 |
| Pituitary dwarfism | D004393 | EFO_1001109 | E23.0 | 1 | 4 | — | 3 | 4 | 11 |
| Failure to thrive | D005183 | — | — | 1 | 1 | 2 | 1 | 2 | 6 |
| Cognitive dysfunction | D060825 | HP_0001268 | G31.84 | — | — | — | 1 | 4 | 5 |
| Heart failure | D006333 | HP_0001635 | I50 | 1 | 2 | — | 1 | 2 | 5 |
| Wounds and injuries | D014947 | — | T14.8 | — | 1 | — | 1 | 3 | 5 |
| Endocrine system diseases | D004700 | EFO_0001379 | E34.9 | — | 2 | 1 | 1 | 1 | 5 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.9 | — | — | — | 2 | 2 | 4 |
Show 28 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carcinoma | D002277 | — | C80.0 | 3 | 8 | 2 | — | 1 | 12 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 5 | 6 | 1 | — | 4 | 12 |
| Syndrome | D013577 | — | — | 2 | 7 | 2 | — | 3 | 12 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | 2 | 1 | — | 9 | 11 |
| Graves ophthalmopathy | D049970 | EFO_1001466 | — | — | 1 | 6 | — | 3 | 10 |
| Eye diseases | D005128 | EFO_0003966 | H44 | — | 1 | 6 | — | 3 | 10 |
| Thyroid diseases | D013959 | HP_0000820 | E00-E07 | — | 1 | 6 | — | 2 | 9 |
| Anorexia | D000855 | HP_0002039 | R63.0 | 2 | 4 | 3 | — | 2 | 8 |
| Anorexia nervosa | D000856 | EFO_0004215 | F50.0 | 2 | 4 | 3 | — | 2 | 8 |
| Covid-19 | D000086382 | — | — | 1 | 4 | 2 | — | 1 | 8 |
Show 37 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 10 | 5 | — | — | 3 | 16 |
| Sarcoma | D012509 | — | — | 1 | 5 | — | — | 2 | 7 |
| Colorectal neoplasms | D015179 | — | — | 2 | 3 | — | — | 1 | 5 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | 2 | 2 | — | — | 2 | 5 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 1 | 3 | — | — | 2 | 5 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 3 | 4 | — | — | — | 5 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | 2 | 3 | — | — | — | 4 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 2 | 4 | — | — | — | 4 |
| Osteoporosis | D010024 | HP_0000939 | M81.0 | 1 | 1 | — | — | 3 | 4 |
| Insulin resistance | D007333 | HP_0000855 | — | 2 | 2 | — | — | 1 | 4 |
Show 94 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Glioma | D005910 | EFO_0000520 | — | 3 | — | — | — | — | 3 |
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | 2 | — | — | — | 1 | 3 |
| Aging | D000375 | GO_0007568 | R41.81 | 1 | — | — | — | 2 | 3 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 1 | — | — | — | 1 | 2 |
| Tendinopathy | D052256 | EFO_1001434 | M77.9 | 1 | — | — | — | 1 | 2 |
| Lipodystrophy | D008060 | HP_0009125 | E88.1 | 1 | — | — | — | 1 | 2 |
| Gastrointestinal neoplasms | D005770 | — | C26.9 | 1 | — | — | — | — | 1 |
| Urogenital neoplasms | D014565 | EFO_0003863 | D07 | 1 | — | — | — | — | 1 |
| Female genital neoplasms | D005833 | — | — | 1 | — | — | — | — | 1 |
| Thoracic neoplasms | D013899 | — | — | 1 | — | — | — | — | 1 |
Show 10 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Metabolic bone diseases | D001851 | HP_0000938 | — | — | — | — | — | 3 | 3 |
| Igg deficiency | D017099 | HP_0004315 | D80.3 | — | — | — | — | 3 | 3 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | — | — | — | — | 2 | 2 |
| Dementia | D003704 | EFO_0003862 | F03 | — | — | — | — | 2 | 2 |
| Bone fractures | D050723 | EFO_0003931 | T14.8 | — | — | — | — | 2 | 2 |
| Graves disease | D006111 | EFO_0004237 | E05.0 | — | — | — | — | 2 | 2 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | — | — | 2 | 2 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | — | — | 2 | 2 |
| Macular degeneration | D008268 | EFO_0001365 | H35.30 | — | — | — | — | 1 | 1 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | — | — | — | 1 | 1 |
Show 101 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Mecasermin |
| INN | mecasermin |
| Description | Mecasermin (INN) (brand name Increlex), also known as recombinant human insulin-like growth factor-1 (rhIGF-1), is a recombinant form of human insulin-like growth factor 1 (IGF-I) which is used in the long-term treatment of growth failure and short stature in children with severe primary IGF-I deficiency, for instance due to growth hormone deficiency or Laron syndrome (growth hormone insensitivity).
|
| Classification | Protein |
| Drug class | growth factors: insulin-like growth factors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201716 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB01277 |
| UNII ID | 7GR9I2683O (ChemIDplus, GSRS) |
Target
Agency Approved
IGF1
IGF1
Organism
Homo sapiens
Gene name
IGF1
Gene synonyms
IBP1
NCBI Gene ID
Protein name
insulin-like growth factor I
Protein synonyms
insulin-like growth factor 1 (somatomedin C), insulin-like growth factor IB, Mechano growth factor, MGF, Somatomedin-C
Uniprot ID
Mouse ortholog
Igf1 (16000)
insulin-like growth factor I (Q8C4U6)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 5,002 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
902 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use